Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 12/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18489972 | 0.83 | CYP11B2 (0.63) | CYP11B2 | |
| SCHEMBL20513563 | 0.76 | CYP11B2 (0.71) | CYP11B2CYP11B1 | |
| SCHEMBL20513565 | 0.76 | CYP11B2 (0.71) | CYP11B2CYP11B1 | |
| SCHEMBL18489908 | 0.74 | CYP11B2 (0.63) | CYP11B2 | |
| SCHEMBL18791026 | 0.71 | GAA (0.53) | CYP11B2CYP11B1 | |
| SCHEMBL18489960 | 0.70 | CYP11B2 (0.60) | CYP11B2 | |
| SCHEMBL20538775 | 0.69 | CYP11B2 (0.49) | CYP11B2 | |
| SCHEMBL18791027 | 0.69 | CYP11B2 (0.48) | CYP11B2CYP11B1 | |
| SCHEMBL18791093 | 0.66 | CYP11B2 (0.66) | CYP11B2CYP11B1GRIN2B | |
| SCHEMBL18489930 | 0.60 | CYP11B2 (1.00) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312503-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-01 | — | — | US | claimed |
| EP-3381904-B1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312503-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | REN, NR3C2, NR5A1 | CYP11B2 8/4885CYP11B1 6/4885GRIN2B 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.